The use of granulocyte-colony-stimulating factor in volunteer unrelated hemopoietic stem cell donors

TitleThe use of granulocyte-colony-stimulating factor in volunteer unrelated hemopoietic stem cell donors
Publication TypeJournal Article
Year of Publication2008
AuthorsPamphilon D, Nacheva E, Navarrete C, Madrigal A, Goldman J
JournalTransfusion
Volume48
Issue7
Pagination1495 - 501
Keywords*Blood Donors, *Granulocyte Colony-Stimulating Factor / ae [Adverse Effects], *Hematopoietic Stem Cell Mobilization, Bone and Bones / de [Drug Effects], Bone and Bones / pp [Physiopathology], Granulocyte Colony-Stimulating Factor / ad [Administration & Dosage], Great Britain, Headache / ci [Chemically Induced], Hematopoietic Stem Cell Transplantation, Humans, Nausea / ci [Chemically Induced], Pain / ci [Chemically Induced], Registries / sn [Statistics & Numerical Data], Vomiting / ci [Chemically Induced]
Abstract

Granulocyte-colony-stimulating factor (G-CSF) is used for the mobilization of hemopoietic stem cells in healthy donors. It has a number of common side effects such as bone pain, which resolve rapidly after administration is discontinued. Recent publications have raised concern that it might act as a trigger for the development of hematologic malignancy in susceptible individuals, possibly by causing genomic instability, but to date there is no evidence that healthy volunteer donors who receive G-CSF are at any increased risk. Ongoing studies aim to confirm whether or not G-CSF can cause chromosomal abnormalities in healthy donors. In the UK, the British Bone Marrow Registry and Anthony Nolan Trust give G-CSF to donors who have agreed to donate peripheral blood stem cells. It is recommended by the UK Registries at present that all stem cell donors are given updated information explaining the current uncertainties with regard to the use of G-CSF before they give informed consent to its administration. This information is based on a statement agreed by the World Marrow Donor Association for use by individual donor registries. Further, it is our current practice that all donors who have received G-CSF, as well as marrow donors who do not, should be under regular review for at least 10 years to allow the occurrence of any long-term adverse events to be documented.

Short TitleThe use of granulocyte-colony-stimulating factor in volunteer unrelated hemopoietic stem cell donors
Notify Library Reference ID1128

Related Incidents